Full-Time

Associate Medical Director

Pharmacovigilance

Immunome

Immunome

201-500 employees

Antibody-based therapeutic discovery and development

Compensation Overview

$222.3k - $294k/yr

No H1B Sponsorship

Bothell, WA, USA

In Person

MD

Category
Biology & Biotech (1)
Required Skills
Biostatistics
Risk Management

Get referred to Immunome

See people who can refer or advise you

Requirements
  • An M.D., D.O., or equivalent medical degree is required.
  • A minimum of 3–5 years of combined clinical and pharmacovigilance experience is required, including at least 2 years in a leadership capacity within the pharmaceutical or biotechnology industry or equivalent.
  • Experience in global pharmacovigilance, including management of pre- and post-marketing products, is required.
  • Experience drafting safety-related regulatory submissions, including Development Safety Update Reports, Periodic Benefit-Risk Evaluation Reports, and Risk Management Plans, and participating in health authority interactions is required.
  • Working knowledge of global pharmacovigilance regulations, including FDA, EMA, ICH, and MHRA requirements, and Good Pharmacovigilance Practice standards is required.
  • Experience in safety data evaluation, signal detection, and benefit-risk assessment methodologies is required.
  • Experience developing and managing safety management teams and vendor partnerships is required.
  • Ability to synthesize complex safety data and manage multiple priorities and projects in a dynamic biotechnology environment is required.
  • Ability to influence cross-functional teams and executive leadership is required.
Responsibilities
  • Provide medical oversight and leadership for safety activities related to assigned products across development and post-marketing phases.
  • Review, interpret, and assess adverse events, serious adverse events, suspected adverse reactions, adverse events of special interest, deaths, discontinuations due to adverse events, and other clinically relevant safety data.
  • Support safety management teams in developing, implementing, and refining pharmacovigilance strategies aligned with corporate and regulatory objectives.
  • Identify, assess, and manage emerging safety signals, leading benefit-risk evaluations and risk mitigation strategies.
  • Serve as the key medical point of contact for safety-related decisions for assigned products.
  • Review safety data and conduct signal detection using clinical trial data, spontaneous reports, literature, and external databases.
  • Identify, evaluate, and escalate emerging safety concerns, including potential signals, event clusters, increased frequency or severity of known risks, and events requiring risk mitigation.
  • Author or contribute to signal evaluation reports, safety assessment memoranda, safety topic reviews, and benefit-risk summaries.
  • Track assigned signals and safety topics through completion, documentation, governance review, and regulatory alignment.
  • Provide medical input into signal evaluation, risk-benefit analyses, and labeling recommendations.
  • Support preparation of aggregate safety reports, including Development Safety Update Reports, Periodic Benefit-Risk Evaluation Reports, IND annual reports, and Risk Management Plans.
  • Draft safety-related sections of regulatory submissions, including INDs, NDAs, BLAs, and MAAs.
  • Partner with Regulatory Affairs during interactions with regulatory authorities on product safety matters.
  • Collaborate with Regulatory Affairs to include appropriate safety information in the Investigator’s Brochure, Informed Consent Forms, and other study documents.
  • Ensure compliance with applicable pharmacovigilance requirements, ICH guidelines, and Good Pharmacovigilance Practice standards.
  • Partner with Clinical Development, Biostatistics, and Medical Affairs to support signal detection, safety data analysis, and communication of emerging findings.
  • Contribute to clinical study design through safety endpoint development and monitoring plans.
  • Collaborate with Translational Sciences and CMC functions to understand mechanistic insights related to safety signals.
  • Communicate key safety updates and risk assessments to internal stakeholders.
  • Participate in internal and external safety meetings, advisory boards, and scientific conferences.
  • Engage with external safety experts, key opinion leaders, and partners on drug safety and risk mitigation strategies.
  • Assist in overseeing external pharmacovigilance vendors and ensuring quality, compliance, and alignment with company standards.
  • Support business development activities by providing safety evaluations of potential in-licensing or collaboration opportunities.
  • Contribute to scientific excellence, collaboration, and regulatory compliance within the pharmacovigilance organization.
  • Contribute to long-term pharmacovigilance planning, including system development, staffing, and process optimization.
  • Contribute to inspection readiness and ensure assigned activities are completed in accordance with company procedures, regulatory requirements, and pharmacovigilance standards.
Desired Qualifications
  • Board certification in Medical Oncology, Hematology, or Immunology is preferred.
  • Oncology or immunology experience is strongly preferred.

Immunome identifies antibodies and their targets by studying the immune systems of patients who recover from diseases, to develop first-in-class therapeutics. Its platform analyzes immune responses to discover novel antibodies and their targets, which are then advanced through research and development in partnership with healthcare and medical research clients. The company’s products work by using antibodies discovered from patients’ immune systems to target diseases, potentially enabling new treatments across oncology and other areas. Immunome differentiates itself through a proprietary discovery platform that extracts clinically relevant antibodies from real patient immune responses, enabling collaborations and licensing deals rather than solely pursuing standalone drug sales. The goal is to bring new antibody therapies to patients by forming partnerships, licensing innovations, and eventually delivering approved therapies.

Company Size

201-500

Company Stage

IPO

Headquarters

Bothell, Washington

Founded

2008

Get referred to Immunome

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA set varegacestat's PDUFA date for April 28, 2027 after strong Phase 3 data.
  • Cash and marketable securities totaled $520.0 million on June 30, 2026, funding into 2028.
  • IM-1617's first patient dosing on June 11, 2026 expands multiple shots on goal.

What critics are saying

  • IM-1617 faces AbbVie's ABBV-400 and Daiichi's crowded TOP1 ADC category by 2027.
  • Immunome burned $120.3 million cash in first-half 2026, despite $520.0 million remaining.
  • A varegacestat rejection would leave Immunome dependent on early-stage programs and recurring dilution.

What makes Immunome unique

  • Varegacestat reached FDA acceptance in July 2026, anchoring Immunome's first near-term asset.
  • IM-1617 targets an undisclosed RTK plus immune exclusion, a rare dual-mechanism ADC.
  • IM-1021 and IM-3050 broaden the platform across ADC and radioligand modalities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Hybrid Work Options

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Holidays

Wellness Program

Mental Health Support

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

Phone/Internet Stipend

Home Office Stipend

Growth & Insights and Company News

Headcount

6 month growth

21%

1 year growth

21%

2 year growth

9%
Associated Press
Aug 11th, 2026
Immunome's varegacestat NDA accepted by FDA with April 2027 target date, $520M cash reserves

Immunome reported Q2 2026 financial results, revealing a net loss of $73.1 million. The biotechnology company held $520.0 million in cash, cash equivalents and marketable securities as of 30 June, expected to fund operations into 2028. The FDA accepted Immunome's application for varegacestat, a desmoid tumour treatment, setting an approval decision date of 28 April 2027. Phase 3 trial data showed an 84% reduction in disease progression risk versus placebo. Research and development expenses totalled $59.9 million for the quarter, whilst general and administrative costs reached $18.3 million. Immunome is advancing three additional clinical-stage programmes, with first patients dosed in trials for IM-1617 and IM-3050. The company plans to submit investigational new drug applications for IM-1340 and IM-1335 by late 2026.

AllSci
Jun 12th, 2026
Immunome debuts first-in-class ADC targeting mystery immune-excluding receptor tyrosine kinase.

Immunome debuts first-in-class ADC targeting mystery immune-excluding receptor tyrosine kinase. June 12, 2026 Bothell, Washington-based Immunome, Inc. (Nasdaq: IMNM) has dosed the first patient in a Phase I first-in-human study of IM-1617, an antibody-drug conjugate directed at an undisclosed receptor tyrosine kinase (RTK) and armed with HC74, the company's proprietary topoisomerase I inhibitor payload. The trial's significance lies partly in its target biology: the RTK in question is described as promoting tumor cell survival while simultaneously mediating immune cell exclusion - a dual role that, if confirmed clinically, could position IM-1617 as relevant in immunologically cold tumors where checkpoint inhibitors have largely failed. The open-label, multicenter dose escalation and expansion study will enroll patients with advanced solid tumors, including colorectal cancer, non-small cell lung cancer, and breast cancer. Primary objectives cover safety, tolerability, and pharmacokinetics, with preliminary anti-tumor activity as an exploratory endpoint. Immunome has not disclosed enrollment targets or an anticipated completion date. Two additional ADC candidates - IM-1340 and IM-1335 - are expected to reach IND submission by mid- and late 2026, respectively, signaling broader platform ambitions beyond this single asset. The rationale for IM-1617 rests on a well-documented but therapeutically underexploited observation: certain receptor tyrosine kinases do not merely sustain tumor cell proliferation but actively remodel the tumor microenvironment to prevent T-cell infiltration. The TAM family RTKs - TYRO3, AXL, and MERTK - are the best-characterized examples, functioning as innate immune checkpoints that suppress dendritic cell and macrophage activity while driving tumor cell survival through PI3K/AKT and RAS/MAPK signaling. AXL in particular has been directly implicated in T-cell exclusion in breast cancer models, where high AXL expression correlated with complete absence of immune infiltration even following radiotherapy. This biology is directly relevant to the three indications Immunome has identified. Approximately 85% of colorectal cancers are microsatellite-stable and immunologically cold, explaining why PD-1/PD-L1 inhibitors have shown no benefit in this population. A comparable subset of non-small cell lung cancers and triple-negative breast cancers similarly fail to respond to immunotherapy, not because of absent antigenicity but because immune cells are physically excluded from the tumor parenchyma. An ADC targeting the RTK responsible for that exclusion could, in principle, simultaneously kill antigen-expressing tumor cells and relieve the suppressive barrier - potentially rendering surviving tumor tissue more susceptible to endogenous or therapeutically induced immune responses. Competitive positioning. The TOP1 inhibitor ADC space is crowded at the payload level but less so at the target level, where differentiation ultimately resides. Daiichi Sankyo and AstraZeneca's DXd platform dominates across HER2, HER3, and TROP2, with multiple Phase II and Phase III assets in NSCLC and breast cancer. AbbVie is advancing ABBV-400, a c-MET-targeted ADC with a proprietary TOP1 inhibitor payload, in NSCLC and colorectal cancer - indications that directly overlap with IM-1617's target population. Because IM-1617's RTK target remains undisclosed, precise competitive mapping is not possible, but the functional description - an RTK driving both survival signaling and immune exclusion - most closely resembles AXL or MERTK biology, neither of which currently has a clinical-stage ADC program of note. Immunome's broader pipeline context is relevant here. Varegacestat, the company's gamma secretase inhibitor for desmoid tumors, has an NDA filed with the US FDA following Phase III data showing 84% reduction in progression risk and a 56% objective response rate - substantially outperforming the current standard. That near-term commercial asset provides a degree of financial and strategic runway for the ADC platform to mature. IM-1021, the ROR1 ADC sharing the HC74 payload with IM-1617, will generate the first human pharmacokinetic and safety data for HC74, which will inform dose selection and linker optimization for subsequent programs including IM-1617. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

Business Wire
May 12th, 2026
Immunome submits NDA for varegacestat after 84% disease progression reduction in Phase 3 trial

Immunome, a biotechnology company developing targeted cancer therapies, reported first quarter 2026 financial results. The company had cash and cash equivalents of $582.7 million as of 31 March, expected to fund operations into 2028. The company submitted a New Drug Application to the US FDA in April 2026 for varegacestat, a treatment for adults with desmoid tumours. Immunome plans to submit a Marketing Authorisation Application to the European Medicines Agency by year-end 2026. Research and development expenses for the quarter were $46.4 million, whilst general and administrative expenses totalled $13.0 million. Immunome reported a net loss of $53.8 million for the quarter. The company is advancing multiple programmes, including Phase 1 trials for IM-1021 and IM-3050, and recently received IND clearance for IM-1617.

Yahoo Finance
Apr 4th, 2026
Immunome CSO sells $204K in shares ahead of Q2 2026 NDA submission

Immunome's Chief Scientific Officer Jack Higgins sold 9,438 shares on 2 April for $204,238, reducing his direct holdings by 30% to 22,000 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan established in December 2025 for financial diversification. The transaction comes as the clinical-stage biotechnology company approaches a significant milestone: its lead candidate varegacestat met the primary endpoint in a Phase 3 trial in December 2025, with an FDA submission planned for the second quarter of 2026. Immunome expects three additional investigational new drug applications and early data from IM-1021 across 2026. The company's stock has risen 250% over the past year, bringing its market capitalisation to $2.40 billion.

Yahoo Finance
Mar 6th, 2026
Immunome cuts 2025 net loss to $212M, files $156M shelf registration ahead of varegacestat NDA

Immunome has reported a reduced full-year net loss of $212.39 million for 2025 and filed a $156.03 million common stock shelf registration linked to an employee stock option plan offering. The biotechnology company also updated investors on progress in its oncology pipeline. The company plans to file a New Drug Application for varegacestat following positive Phase 3 data, with multiple solid tumour investigational new drug applications also in development. However, Immunome remains deeply unprofitable despite the narrower losses. The shelf registration raises concerns about potential equity dilution and ownership overhang. Fair value estimates from analysts vary widely, ranging from approximately $29 to over $215 per share, reflecting significant uncertainty around the company's prospects as it advances its high-risk oncology platform.